Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase

Aim. To analyse resistance to imatinib therapy, efficacy and safety of dasatinib. Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008. Results. Lethal outcomes during dasatinib tre...

Full description

Bibliographic Details
Main Authors: Ol'ga Yur'evna Vinogradova, Anna Grigor'evna Turkina, Aleksandra Valer'evna Vorontsova, Ekaterina Yur'evna Chelysheva, Galina Anatol'evna Gusarova, S V Kuznetsov, Svetlana Rudol'fovna Goryacheva, Manana Aleksandrovna Sokolova, Evgeniy Mikhaylovich Abakumov, Ol'ga Veniaminovna Stakhina, Elena Vasil'evna Domracheva, Andrey Vital'evich Misyurin, Nina Dmitrievna Khoroshko, O Yu Vinogradova, A G Turkina, A V Vorontsova, E Yu Chelysheva, G A Gusarova, S R Goryacheva, M A Sokolova, E M Abakumov, O V Stakhina, E V Domracheva, A V Misyurin, N D Khoroshko
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2009-07-01
Series:Терапевтический архив
Subjects:
chronic myeloid leukemia
tyrosinkinase inhibitors
dasatinib
ph-positive clone
bcr-abl gene
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/30380

Internet

https://ter-arkhiv.ru/0040-3660/article/view/30380

Similar Items